ROCHESTER, MI--(Marketwire -05/09/12)- OPTIMIZERx Corp. (OTC.BB: OPRX) continues to expand their proprietary SampleMD technology to enable more doctors to add and distribute savings and patient education right within their ePrescribing workflow. The Company is on track to launch this technology within another leading ePrescribe platform that will reach an additional 35,000 doctors within 2nd quarter 2012. More prescribers are looking for an alternative to drug samples that are being restricted or only serving select patients versus the much broader savings and support they can provide when SampleMD is electronically integrated within their EMR or ePrescribe platform.
Additionally, more pharmaceutical manufacturers are recognizing SampleMD as a powerful new channel to reach more doctors and providers. New manufacturers include Pfizer, Astellas and Bristol-Myers Squibb. Pharmaceutical companies understand the importance of increasing patient affordability to promote adherence and better health outcomes. Clients are also excited about SampleMD's new programs to include patient education and latest product information, particularly for physicians who limit drug rep access.
About OPTIMIZERx Corp.
OPTIMIZERx Corp. provides unique consumer and physician platforms to help patients better afford and comply with their medicines and healthcare products, while offering pharmaceutical and healthcare companies effective ways to expand patient awareness, access and adherence to their brands. For more information, please go to www.optimizerxcorp.com.
This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended and such section 21E of the Securities Act of 1934, amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.